David W. Cescon
机构: Medical Oncologist and Clinician Scientist, Princess Margaret Cancer Centre, University of Toronto
每年引用次数
引用次数
引用: 14,434
H-指数: 52
I10-指数 : 110
出版物: 286
Mutations in noncoding cis-regulatory elements reveal cancer driver cistromes in luminal breast cancer
Samah El Ghamrasni , Rene Quevedo , James Hawley , Parisa Mazrooei
Molecular Cancer Research 20 ( 1) 102 -113
3
2022
Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy by PD-L1 Combined Positive Scores 1-9, 10-19, and>= 20 for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer: KEYNOTE-355 Subgroup Analysis
Sherene Loi , DavidW Cescon , Hope S Rugo , Zbigniew Nowecki
Asia-Pacific Journal Of Clinical Oncology
2022
Pembrolizumab monotherapy in metastatic triple-negative breast cancer.
Eitan Amir , David W Cescon ,
Lancet Oncology 22 ( 4) 415 -417
2021
Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy
Lin Zheng , Zibo Chen , Masanori Kawakami , Yulong Chen
Molecular Cancer Therapeutics 18 ( 10) 1775 -1786
6
2019
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes , David W Cescon , Hope S Rugo , Zbigniew Nowecki
The Lancet 396 ( 10265) 1817 -1828
743
2020
Abstract PD2-03: CDK4/6 inhibitor-resistant ER+ breast cancer cell lines are hypersensitive to TTK inhibition
Isabel Soria Bretones , Kelsie L Thu , Jennifer Silvester , Reza Kiarash
Cancer Research 80
2020
Gene Expression Analyses in Breast Cancer: Sample Matters.
Benjamin Haibe-Kains , David W Cescon
JNCI Cancer Spectrum 2 ( 2)
2018
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Ryan J O Dowling , Joseph A Sparano , Pamela J Goodwin , Francois-Clement Bidard
JNCI Cancer Spectrum 3 ( 4)
1
2019
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Ryan J O Dowling , Kevin Kalinsky , Daniel F Hayes , Francois-Clement Bidard
JNCI Cancer Spectrum 3 ( 4)
4
2019
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Hadar Goldvaser , Tristan A Barnes , Boštjan Šeruga , David W Cescon
Journal of the National Cancer Institute 110 ( 1) 31 -39
129
2018
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer
Swneke D Bailey , Kinjal Desai , Ken J Kron , Parisa Mazrooei
Nature Genetics 48 ( 10) 1260 -1266
56
2016
Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids
Elisabeth Prince , Jennifer Cruickshank , Wail Ba-Alawi , Kelsey Hodgson
Nature communications 13 ( 1) 1466
16
2022
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
Qin Wu , David Y Nie , Wail Ba-Alawi , YiShuai Ji
Nature Chemical Biology 18 ( 8) 821 -830
14
2022
Current treatment and future trends of immunotherapy in breast cancer
Mitchell J Elliott , Brooke Wilson , David W Cescon
Current Cancer Drug Targets 22 ( 8) 667 -677
2
2022
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
Javier Cortes , Hope S Rugo , David W Cescon , Seock-Ah Im
New England Journal of Medicine 387 ( 3) 217 -226
53
2022
Inhibition of the MNK1/2--eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
Sathyen A Prabhu , Omar Moussa , Christophe Gonçalves , Judith H LaPierre
Molecular Cancer Therapeutics 22 ( 2) 192 -204
2023
Clinical activity of mitogen-activated protein kinase--targeted therapies in patients with non--V600 BRAF-mutant tumors
Matthew Dankner , Yifan Wang , Rouhi Fazelzad , Benny Johnson
JCO Precision Oncology 6 e2200107
3
2022
Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer
Nicholas Cheng , Kimberly Skead , Althaf Singhawansa , Tom W Ouellette
medRxiv 2023 -01
2023
Пембролизумаб плюс химиотерапия в лечении трижды негативного рака молочной железы
Javier Cortes , Hope S Rugo , David W Cescon , Mastura M Yusof
New England Journal of Medicine 387 ( 3) 217 -226
2022
Development of novel agents for the treatment of early estrogen receptor positive breast cancer
Mitchell J Elliott , David W Cescon
The Breast 62 S34 -S42
1
2022